Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vir Biotechnology Inc VIR

Healthcare Biotechnology
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical... see more

Recent & Breaking News (NDAQ:VIR)

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022

GlobeNewswire October 28, 2022

Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A

GlobeNewswire October 18, 2022

Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference

GlobeNewswire October 11, 2022

Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats

GlobeNewswire October 4, 2022

Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection

GlobeNewswire September 22, 2022

Vir Biotechnology to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

GlobeNewswire September 6, 2022

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results

GlobeNewswire August 9, 2022

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial Results on August 4, 2022

GlobeNewswire July 21, 2022

Vir Biotechnology Announces Transition of Chief Scientific Officer

GlobeNewswire July 14, 2022

Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program

GlobeNewswire June 25, 2022

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress(TM) 2022

GlobeNewswire June 8, 2022

Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details

GlobeNewswire May 18, 2022

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results

GlobeNewswire May 5, 2022

Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day

GlobeNewswire April 27, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR

PR Newswire April 23, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vir Biotechnology, Inc. - VIR

Newsfile April 21, 2022

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022

GlobeNewswire April 21, 2022

Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day

GlobeNewswire April 13, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Vir Biotechnology, Inc. - VIR

PR Newswire April 11, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Vir Biotechnology, Inc. - VIR

Newsfile April 9, 2022